Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations

BACKGROUND AND PURPOSE: Currently, there are no licensed vaccines and limited antivirals for the treatment of COVID‐19. Heparin (delivered systemically) is currently used to treat anticoagulant anomalies in COVID‐19 patients. Additionally, in the United Kingdom, Brazil and Australia, nebulised unfra...

Descripción completa

Detalles Bibliográficos
Autores principales: Tree, Julia A., Turnbull, Jeremy E., Buttigieg, Karen R., Elmore, Michael J., Coombes, Naomi, Hogwood, John, Mycroft‐West, Courtney J., Lima, Marcelo A., Skidmore, Mark A., Karlsson, Richard, Chen, Yen‐Hsi, Yang, Zhang, Spalluto, Cosma Mirella, Staples, Karl J., Yates, Edwin A., Gray, Elaine, Singh, Dave, Wilkinson, Tom, Page, Clive P., Carroll, Miles W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328389/
https://www.ncbi.nlm.nih.gov/pubmed/33125711
http://dx.doi.org/10.1111/bph.15304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328389/
https://www.ncbi.nlm.nih.gov/pubmed/33125711
http://dx.doi.org/10.1111/bph.15304

Ejemplares similares